PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220			
PWO-25629	ACTION as we	well as, where applicable, item 5 below.			
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)			
PCT/JP2005/003819	28/02/2005 05/03/2004				
Applicant					
FUJISAWA PHARMACEUTICAL CO	D., LTD.	· · · · · · · · · · · · · · · · · · ·			
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searching Au ansmitted to the International Bureau.	thority and is transmitted to the applicant			
This International Search Report consists	of a total of sheets.	•			
X It is also accompanied by	a copy of each prior art document cited in th	s report.			
	international search was carried out on the bless otherwise indicated under this item.	asis of the international application in the			
The international this Authority (Ru		slation of the international application furnished to			
b. With regard to any nucle	otide and/or amino acid sequence disclose	d in the international application, see Box No. I.			
· 2. Certain claims were fou	ind unsearchable (See Box II).				
3. Unity of invention is lac	cking (see Box III).				
4. With regard to the title ,					
X the text is approved as s	ubmitted by the applicant.				
the text has been established by this Authority to read as follows:					
	ν.	•			
	•				
W.					
5. With regard to the abstract,		•			
	submitted by the applicant.				
the text has been establi	ished, according to Rule 38.2(b), by this Auth	ority as it appears in Box No. IV. The applicant			
may, within one month it	om the date of mailing of this international se	arch report, submit comments to this Authority.			
6. With regard to the drawings,					
a. the figure of the drawings to be published with the abstract is Figure No					
as suggested by	the applicant.				
	his Authority, because the applicant failed to				
· ·	his Authority, because this figure better chara	cterizes the invention.			
b. X none of the figures is to	be published with the abstract.				

Form PCT/ISA/210 (first sheet) (January 2004)

	CO7K16/44 GO1N33/53 C12N5/16			
According to	International Patent Classification (IPC) or to both national classifica	ation and IPC		
B. FIELDS	SEARCHED			
Minimum do IPC 7	cumentation searched (classification system followed by classification CO7K GO1N	on symbols)		
	ion searched other than minimum documentation to the extent that s ata base consulted during the international search (name of data base)			
	ternal, CHEM ABS Data, BIOSIS, EMBAS			
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.	
Χ .	BIRSAN T ET AL: "In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates"		1–18	
	TRANSPLANT INTERNATIONAL 01 MAY 2003 GERMANY, vol. 16, no. 5, 1 May 2003 (2003-05-01), pages 354-360, XP002327441 ISSN: 0934-0874 abstract			
	page 355, right-hand column, para	agraph 3		
	-	-/		
X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.	
Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance.		'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another		X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone Y* document of particular relevance; the claimed invention		
O docum other	on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but	cannot be considered to involve an in document is combined with one or m ments, such combination being obvio in the art.	ventive step when the ore other such docu-	
later than the priority date claimed		& document member of the same patent family Date of mailing of the international search report		
	actual completion of the international search May 2005	11/07/2005	лон героп	
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer		
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Bayer, A		

2

PCT/JP2005/003819

·	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT		10
Category °	Citation of document, with indication, where appropriate, of the relevant passages .	<u>.</u>	Relevant to claim No.
Α	JOHNSTON A ET AL: "Immunosuppressant drugs - The role of therapeutic drug monitoring" BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2001 UNITED KINGDOM, vol. 52, no. SUPPL. 1, 2001, pages		
	61S-73S, XP002327442 ISSN: 0306-5251 the whole document	•	
1	ALAK A M: "MEASUREMENT OF TACROLIMUS (FK506) AND ITS METABOLITES: A REVIEW OF ASSAY DEVELOPMENT AND APPLICATION IN	·	·
	THERAPEUTIC DRUG MONITORING AND PHARMACOKINETIC STUDIES" THERAPEUTIC DRUG MONITORING, NEW YORK, NY, US,		
	vol. 19, no. 3, June 1997 (1997-06), pages 338-351, XP000973285 ISSN: 0163-4356 the whole document		
4	DETERS MICHAEL ET AL: "Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants."		
	ANALYTICA CHIMICA ACTA, vol. 492, no. 1-2, 15 September 2003 (2003-09-15), pages 133-145, XP002327443 ISSN: 0003-2670 the whole document		
			·
	·		

2